NBIX vs REGN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

REGN is the larger of the two ($93.98B market cap): the incumbent the market prices for continued execution (12.85x forward earnings, beta 0.09). NBIX is the smaller challenger ($16.95B), priced similarly on forward earnings (13.61x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

NBIX vs REGN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricNBIXREGNWhat it tells you
Market cap$16.95B$93.98BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E13.6112.85Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E24.8420.08Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.330.09Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range71% of range79% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.372.72How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how NBIX and REGN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NBIX and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NBIX and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Neurocrine Biosciences (NBIX) do?

Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease. Ingrezza generated about $657 million in net product sales in Q1 2026, up roughly 20 percent year over year, and in September 2026 management cited raised full-year 2026 guidance of about $2.825 to $2.875 billion. A second product, Crenessity (crinecerfont), launched for classic congenital adrenal hyperplasia and had reached an annualized revenue run rate of about $750 million six quarters into its launch. A third, Vykat XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome, arrived with the roughly $2.9 billion Soleno Therapeutics acquisition and runs at about $400 million annualized. Total revenue rose to ~$959 million in the June 2026 quarter, up ~40% year over year, and trailing-twelve-month revenue reached ~$3.37 billion with net income of ~$706 million.

Full NBIX guide

What does Regeneron Pharmaceuticals (REGN) do?

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base. Total revenue then stepped up to about $4.29 billion in Q2 2026, up roughly 17% year over year, taking trailing twelve-month revenue to about $15.5 billion and net income to about $4.3 billion.

Full REGN guide

NBIX vs REGN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • NBIX drivers: Ingrezza is a durable, growing cash engine; Crenessity adds a real second product.
  • REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. For REGN, the clearest risk is Eylea biosimilar erosion.

NBIX or REGN: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NBIX if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NBIX and REGN guides.

NBIX vs REGN: the full fundamentals

NBIX. Neurocrine trades near 20 times trailing and about 11 times forward earnings, a lower multiple than in mid-2026 after the shares fell ~24% over three months, as investors price in the 2029 Medicare cut to Ingrezza and the Soleno deal's execution. Third-quarter results are due November 2, 2026, with consensus near ~$1.04 billion of revenue and EPS of ~$2.72; the 29 analysts covering it average a strong-buy rating with a mean target near $207.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron has beaten EPS estimates in each of the last four quarters, most sharply in Q2 2026 (about $14.29 against $10.21), and the shares rose about 18% over three months to roughly $794, up about 40% over a year. Consensus for Q3 2026, due October 30, sits near $16.06 of EPS on about $4.54 billion of revenue, and the ~13x forward P/E reflects the market weighing strong Dupixent growth against Eylea biosimilar erosion expected to accelerate around the fourth quarter of 2026.

Headline figures (approximate, October 2026): NBIX shows revenue (ttm) ~$3.37 billion, revenue growth ~40% year over year in Q2 2026 (~$959 million), ingrezza 2026 guidance ~$2.825-2.875 billion, margins Gross ~64%; operating ~22%; net ~21%; REGN shows total revenue (ttm) ~$15.5 billion, q2 2026 total revenue ~$4.29 billion (up ~17% YoY), q2 2026 eps vs estimate ~$14.29 vs ~$10.21, net income (ttm) ~$4.3 billion (~28% net margin).

The bottom line: NBIX vs REGN

NBIX and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NBIX and REGN exposure against your real portfolio. It is not an investment adviser.

Wondering how NBIX or REGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Neurocrine Biosciences

Ask Walnut's AI anything about NBIX and see how it fits what you own.

FAQ

What is the difference between NBIX and REGN?

+

Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is NBIX or REGN the better stock?

+

Neither is universally better. REGN is the larger incumbent; NBIX is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, NBIX or REGN?

+

On forward P/E (as of November 2026), NBIX trades at 13.61x and REGN at 12.85x, so REGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both NBIX and REGN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of NBIX vs REGN?

+

NBIX: The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. That reform is already scheduled: Ingrezza's Medicare negotiated price takes effect in 2029, management expects revenue to decline that year, and rival Austedo reaches its negotiated price two years earlier, in 2027. CNS drug development is also high-risk, and a single Phase 3 miss for the muscarinic or depression programs could sharply reset expectations. The Soleno acquisition adds integration and execution risk, with Vykat XR sales expected to be flat near term and safety reports under scrutiny, and the deal cut the cash balance to ~$390 million. The stock can be volatile around trial readouts, label decisions, and guidance updates; it fell ~24% over the three months to mid-October 2026. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NBIX or REGN; figures are approximate and dated (as of November 2026). Verify current data before investing.